Researchers and Australia’s Noumi are investigating the potential of lactoferrin, a milk protein, to prevent COVID-19 and common colds. This study, in partnership with the Hunter Medical Research Institute, explores how lactoferrin’s antiviral properties could be harnessed to enhance immune responses and prevent respiratory infections. The research includes developing new delivery methods, such as nasal sprays, and highlights the economic potential for the dairy industry in utilizing lactoferrin.
Scientists and one of Australia’s largest dairy processors, Noumi, are investigating whether a milk protein could help prevent COVID-19 and the common cold. This research, conducted in partnership with the Hunter Medical Research Institute at the University of Newcastle, challenges the old belief that dairy should be avoided when sick.
Lactoferrin: A New Frontier in Antiviral Research
Lactoferrin, a milk protein discovered over 80 years ago, is the focus of this research. Known for its antiviral, antibacterial, antifungal, antiparasitic, and anti-inflammatory properties, lactoferrin is already used in infant milk formula, skincare products, protein powders, and supplements. The current study aims to evaluate its effectiveness against specific viruses like coronavirus and those causing the common cold.
How Lactoferrin Works Against Viruses
Lactoferrin enhances the body’s immune response to viral respiratory diseases. It binds to viruses, preventing them from attaching to cells, and if the virus does attach, lactoferrin interacts with human cell components to hinder viral entry. This mechanism suggests that increased lactoferrin consumption could bolster the immune system’s ability to fight infections.
Developing Effective Delivery Methods for Lactoferrin
Researchers are exploring various methods to administer lactoferrin, including a nasal spray. The goal is to determine if a daily dose of lactoferrin, whether through food, capsules, or other forms, can significantly boost immune defenses and offer protection against respiratory illnesses.
Market Opportunities and Challenges for Lactoferrin
The CSIRO views the expansion of protein products, like lactoferrin, as a significant $13 billion opportunity for Australia. While the use of lactoferrin as an antiviral is promising, developing and scaling such products presents challenges. Production costs and technological barriers often impede the transition from clinical trials to mass-market availability.
Impact on the Dairy Industry
Noumi, Australia’s largest long-life milk company, sees lactoferrin as a valuable opportunity for innovation in the dairy sector. Lactoferrin, often a byproduct in milk, can be sold at high prices, making it a potential revenue stream. However, producing lactoferrin requires substantial amounts of milk, necessitating more efficient and sustainable production methods.
Looking Ahead: Future Prospects for Lactoferrin-Based Antivirals
As global demand for lactoferrin grows, finding sustainable ways to produce it becomes crucial. The dairy industry faces both challenges and opportunities in adapting to new uses for milk proteins. Researchers and industry leaders are optimistic about the potential of lactoferrin to become a key player in antiviral treatments, paving the way for future advancements in both dairy and medical fields.
